1. Home
  2. SYF vs BIIB Comparison

SYF vs BIIB Comparison

Compare SYF & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SYF

Synchrony Financial

HOLD

Current Price

$72.46

Market Cap

24.0B

Sector

Finance

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$172.52

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYF
BIIB
Founded
1932
1978
Country
United States
United States
Employees
20000
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0B
27.1B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
SYF
BIIB
Price
$72.46
$172.52
Analyst Decision
Buy
Buy
Analyst Count
19
27
Target Price
$84.11
$197.46
AVG Volume (30 Days)
3.2M
1.0M
Earning Date
04-21-2026
04-29-2026
Dividend Yield
1.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$86.77
N/A
Revenue Next Year
$4.96
N/A
P/E Ratio
$7.85
$20.13
Revenue Growth
N/A
2.22
52 Week Low
$46.08
$114.66
52 Week High
$88.77
$202.41

Technical Indicators

Market Signals
Indicator
SYF
BIIB
Relative Strength Index (RSI) 65.33 40.08
Support Level $71.85 $170.99
Resistance Level $75.21 $188.76
Average True Range (ATR) 1.55 5.70
MACD 0.95 -1.02
Stochastic Oscillator 96.56 18.09

Price Performance

Historical Comparison
SYF
BIIB

About SYF Synchrony Financial

Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: